BWXT Lifts 2026 Revenue Target to ~$3.8B, Tops Q2 EPS, and Strikes $800M Medical Unit Sale
BWXT sits 19% above its 52-week low of $143.07.
Summary
BWX Technologies posted Q2 2026 revenue of $901.6M and adjusted EPS of $1.07, raised its full-year revenue guide to ~$3.8B, closed the PCG acquisition, and announced an $800M sale of its medical business to Nordic Capital.
Key Events · Earnings and Guidance · BWXT
-
Q2 Revenue Slightly Misses, EPS Beats
Revenue of $901.6M missed consensus by $1.0M, but adjusted EPS of $1.07 beat by $0.02, driven by strong Commercial Operations growth.
-
Full-Year Revenue Guidance Raised
Management raised 2026 revenue guidance to approximately $3.8 billion, up from prior view, reflecting robust demand and acquisition contributions.
-
Medical Business Sale to Nordic Capital
Entered definitive agreement to sell medical business for up to $800 million, retaining a minority interest; expected to close in 2026 or early 2027, subject to regulatory approvals.
-
PCG Acquisition Completed
Completed acquisition of Precision Components Group on July 1, 2026, expanding U.S. commercial nuclear manufacturing capacity.
Analysis · BWXT · Technology
A mixed second quarter saw revenue come in just shy of consensus, but a solid earnings beat and an upward revision to the full-year revenue outlook to approximately $3.8 billion signal underlying momentum. Two transformative deals punctuated the period: the completed acquisition of Precision Components Group, which bolsters U.S. commercial nuclear manufacturing capacity, and a definitive agreement to sell the medical business to Nordic Capital for up to $800 million while retaining a minority stake. The backlog swelled to $8.4 billion from $7.3 billion at year-end, reflecting robust demand across government and commercial nuclear operations. The medical divestiture sharpens the focus on core nuclear markets and could unlock significant value, though execution risk lingers with regulatory approvals still pending.
At the time of this filing, BWXT was trading at $170.00 on NYSE in the Technology sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $143.07 to $241.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.